PROZAC WEEKLY

Compare PROZAC WEEKLY  to:
Compare
Compare

Generic Name for PROZAC WEEKLY

Fluoxetine (as HCl) 90mg; caps containing e-c delayed-release pellets.

Legal Classification:

Rx

Pharmacological Class for PROZAC WEEKLY

SSRI.

Manufacturer of PROZAC WEEKLY

Dista Products Company

Indications for PROZAC WEEKLY

Maintenance phase of depression.

Adult dose for PROZAC WEEKLY

90mg once weekly. Start 7 days after last dose of fluoxetine 20mg (when switching from daily dosing).

Children's dosing for PROZAC WEEKLY

Not recommended.

Also:

Contraindications for PROZAC WEEKLY

During or within 14 days of MAOIs. Concomitant pimozide, thioridazine (may cause QTc prolongation).

Warnings/Precautions for PROZAC WEEKLY

Monitor for serotonin syndrome or neuroleptic malignant syndrome-like signs/symptoms; discontinue if occurs. Discontinue if unexplained allergic reaction occurs. Renal or hepatic dysfunction. History of seizures or mania/hypomania. Recent MI. Unstable heart disease. ECT (prolonged seizures). Reevaluate periodically in long-term use. Avoid abrupt cessation. Monitor weight. Conditions that affect metabolism or hemodynamic responses. Volume depletion. Diabetes. Suicidal tendencies (monitor). Write ℞ for smallest practical amount. Elderly. Labor & delivery. Pregnancy (Cat.C; avoid 3rd trimester or consider lower dose; see literature for effects on neonate). Nursing mothers: not recommended.

Interactions for PROZAC WEEKLY

See Contraindications. Do not start MAOI or thioridazine within at least 5 weeks of discontinuing fluoxetine. Concomitant SSRIs, SNRIs, tryptophan: not recommended. May potentiate protein-bound drugs (eg, warfarin, digoxin) and those metabolized by CYP2D6 (eg, tricyclics, vinblastine, flecainide). May potentiate carbamazepine, phenytoin. Monitor lithium, phenytoin, warfarin, tricyclics. Caution with benzodiazepines (eg, diazepam, alprazolam), antipsychotics (eg, clozapine, haloperidol), other CNS drugs. Increased risk of bleeding with NSAIDs, aspirin, warfarin, others that affect coagulation. Caution with triptans, linezolid, lithium, tramadol, St. John's wort; may cause serotonin syndrome (eg, weakness, incoordination, hyperreflexia). Hyponatremia with diuretics.

Adverse Reactions for PROZAC WEEKLY

Nausea, CNS stimulation (eg, anxiety, nervousness, insomnia), somnolence, headache, mania/hypomania, anorexia, weight loss, tremor, asthenia, sexual dysfunction, sweating, GI disturbances, respiratory symptoms, motor impairment, serum sickness, hypo- or hyperglycemia, rash (may be serious), urticaria, pruritus; rarely: platelet dysfunction. Children: thirst, hyperkinesia, agitation, personality disorder, epistaxis, urinary frequency, menorrhagia.

How is PROZAC WEEKLY supplied?

Caps 10mg—100
20mg—30, 100, 2000
40mg—30
Liq—4oz
Weekly—4

Related Disease:

Depression

Related Resources

FDA warns of aseptic meningitis risk with Lamictal

August 13, 2010

The FDA has informed healthcare professionals and patients that Lamictal (lamotrigine, from GlaxoSmithKline) can cause aseptic meningitis.

Oleptro available for major depressive disorder

August 10, 2010

Labopharm and Angelini announced the launch of Oleptro (trazodone HCl extended-release tablets) for the treatment of major depressive disorder (MDD) in adults.

Phase 3 study of TC-5214 for major depressive disorder (MDD)

June 23, 2010

AstraZeneca and Targacept announced the enrollment of the first patient in their Phase 3 development program for TC-5214 as an adjunct treatment for major depressive disorder (MDD) in patients with an inadequate response to first-line therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin/norepinephrine reuptake inhibitor (SNRI).

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

NDA submitted for vilazodone for major depressive disorder (MDD)

March 23, 2010

Clinical Data Inc. announced that a New Drug Application (NDA) has been submitted to the FDA seeking approval of vilazodone for the treatment of major depressive disorder (MDD).

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions